The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...

The recent litigation concerning the government’s 340B Rebate Model Pilot Program (the Rebate Program), as further described ...

Henry Ford Health, one of Michigan’s largest 340B health systems, spent $90 million on a naming and branding partnership with ...

On February 2, 2024, the “gang of six”—a bipartisan group of six senators who have traditionally championed reforms to the 340B program 1 —introduced a discussion draft of a bill that would modify the ...

The 340B Drug Pricing Program was developed more than three decades ago to help improve access to medicines for vulnerable patients 4 via manufacturer discounts to specific nonprofit hospitals and ...

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...

Hospitals are up in arms over new guidance issued by the Health Resources and Services Administration on Thursday that could restrict the eligibility of their outpatient clinics for drug discounts in ...

The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and ...

Regulators on Thursday finalized a flurry of rules with sweeping implications for U.S. providers, including Medicare reimbursement rates for hospital outpatient sites and doctor’s offices and a ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

Rescription, Inc., a leading innovator in pharmacy benefit management, is proud to announce it has been awarded a U.S.

Evolving trends in prostate cancer: Disparities across income levels and global regions (1990-2019). This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary Cancers Symposium. This abstract ...